VeriMomБезопасен ли tasmannia lanceolata leaf extract при беременности?
No harmonised CLP reproductive classification (ECHA Annex VI) or SCCS/CIR safety assessment was identified for Tasmannia lanceolata leaf extract. A search of peer‑reviewed literature (PubMed) yields no controlled reproductive or developmental toxicity studies implicating this botanical; dominant constituents (e.g., polygodial) are described for irritancy/antimicrobial activity but not for teratogenicity. Therefore default hazard/mechanism scores are 0 and expected exposure from topical cosmetic use is low (e=0). Sources: ECHA Annex VI (no harmonised CLP entry), PubMed, CosIng, PubChem.
Pregnancy-safe products containing tasmannia lanceolata leaf extract
Related ingredients
Frequently asked questions
- Безопасен ли tasmannia lanceolata leaf extract при беременности?
- No harmonised CLP reproductive classification (ECHA Annex VI) or SCCS/CIR safety assessment was identified for Tasmannia lanceolata leaf extract. A search of peer‑reviewed literature (PubMed) yields no controlled reproductive or developmental toxicity studies implicating this botanical; dominant constituents (e.g., polygodial) are described for irritancy/antimicrobial activity but not for teratogenicity. Therefore default hazard/mechanism scores are 0 and expected exposure from topical cosmetic use is low (e=0). Sources: ECHA Annex VI (no harmonised CLP entry), PubMed, CosIng, PubChem.
- Безопасен ли tasmannia lanceolata leaf extract при грудном вскармливании?
- No evidence in regulatory sources or peer‑reviewed literature of lactation-specific risks or transfer via breast milk for this ingredient. No harmonised classifications or CIR/SCCS opinions raising reproductive/lactational concerns. Topical cosmetic exposure is expected to be low for mother (e=0). Sources: PubMed, CosIng, ECHA Annex VI.
- Безопасен ли tasmannia lanceolata leaf extract для кожи малыша?
- No infant‑specific reproductive or developmental toxicity data found. Hazard and mechanism remain 0 due to absence of evidence of reproductive/ED effects. Exposure score increased by +1 (e=1) for 0–3‑year‑old skin because infant barrier immaturity increases potential percutaneous uptake relative to adults and because the ingredient is not an inherently non‑absorbable mineral; however, no data quantify neonatal absorption. Note: known concerns for this extract are primarily topical irritancy/allergenicity (from compositional constituents such as polygodial) rather than reproductive toxicity. Sources: PubMed, CosIng, EWG.
- Как VeriMom оценивает tasmannia lanceolata leaf extract?
- VeriMom оценивает tasmannia lanceolata leaf extract в 100/100 (без известных рисков) на основе EU CosIng, классификаций ECHA и исследований PubMed.
- Какие безопасные альтернативы tasmannia lanceolata leaf extract при беременности?
- См. наш список безопасных альтернатив tasmannia lanceolata leaf extract с аналогичной функцией и классификацией без известных рисков.
Проверь любой состав за 2 секунды
Скачай VeriMom бесплатно — отсканируй любой продукт и мгновенно получи оценку безопасности при беременности.
Медицинская оговорка
Данная информация предоставлена исключительно в образовательных целях и не является медицинской рекомендацией. Оценки безопасности основаны на общедоступных данных и могут не отражать все риски. Всегда консультируйтесь с вашим врачом перед использованием любых средств во время беременности или грудного вскармливания.